The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.